Sweden · Delayed Price · Currency is SEK IRLAB Therapeutics AB Earnings Call Transcripts
Fiscal Year 2025
-
Pipeline advanced with five CNS drug candidates, strong patent protection, and SEK 60M raised. Mestopetam and Piripramat progress toward late-stage trials, IRL757 study in apathy to start Q4, and business development prioritized for partnerships.
-
EirLab Therapeutics advanced its Parkinson's pipeline in Q1, securing strong regulatory feedback, positive clinical data, and robust funding for key programs, while implementing cost controls and prioritizing late-stage assets. Patent protection remains a core strength.
Fiscal Year 2024
-
IRLAB Therapeutics reported strong pipeline progress in Parkinson's disease, with positive regulatory and payer feedback, increased net sales, and imminent Phase 2b data for Pirepimat. Cash position remains solid, and key programs are advancing as planned.
-
IRlab advanced its Parkinson's pipeline in Q3, securing new patents, progressing clinical trials, and improving cash flow, with key readouts and financing needs ahead.
-
IR Lab advanced three clinical programs, secured full funding for IRL757 via MSRD collaboration, and maintained a strong cash position. Key milestones are expected in the next 12–18 months, with business development and partnerships as strategic priorities.